4.4 Article

Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence

Journal

MEDICAL DECISION MAKING
Volume 38, Issue 7, Pages 822-833

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/0272989X18790963

Keywords

Bayesian network; breast cancer; locoregional recurrence; logistic regression; machine learning; risk prediction; second primary

Ask authors/readers for more resources

Purpose. For individualized follow-up, accurate prediction of locoregional recurrence (LRR) and second primary (SP) breast cancer risk is required. Current prediction models employ regression, but with large data sets, machine-learning techniques such as Bayesian Networks (BNs) may be better alternatives. In this study, logistic regression was compared with different BNs, built with network classifiers and constraint- and score-based algorithms. Methods. Women diagnosed with early breast cancer between 2003 and 2006 were selected from the Netherlands Cancer Registry (NCR) (N = 37,320). BN structures were developed using 1) Bayesian network classifiers, 2) correlation coefficients with different cutoffs, 3) constraint-based learning algorithms, and 4) score-based learning algorithms. The different models were compared with logistic regression using the area under the receiver operating characteristic curve, an external validation set obtained from the NCR from 2007 and 2008 (N = 12,308), and subgroup analyses for a high- and low-risk group. Results. The BNs with the most links showed the best performance in both LRR and SP prediction (c-statistic of 0.76 for LRR and 0.69 for SP). In the external validation, logistic regression generally outperformed the BNs in both SP and LRR (c-statistic of 0.71 for LRR and 0.64 for SP). The differences were nonetheless small. Although logistic regression performed best on most parts of the subgroup analysis, BNs outperformed regression with respect to average risk for SP prediction in low- and high-risk groups. Conclusions. Although estimates of regression coefficients depend on other independent variables, there is no assumed dependence relationship between coefficient estimators and the change in value of other variables as in the case of BNs. Nonetheless, this analysis suggests that regression is still more accurate or at least as accurate as BNs for risk estimation for both LRRs and SP tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Costs of Hospital-Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System

Michelle M. A. Kip, Sytze de Roock, Inge van den Berg, Gillian Currie, Deborah A. Marshall, Luiza R. Grazziotin, Marinka Twilt, Rae S. M. Yeung, Susanne M. Benseler, Sebastiaan J. Vastert, Nico Wulffraat, Joost F. Swart, Maarten J. IJzerman

Summary: This study quantifies the costs of hospital-associated care for juvenile idiopathic arthritis (JIA) and finds significant variations in costs among individuals and subtypes. Systemic JIA has the highest annual costs, primarily attributed to medication, and costs are highest in the first month after JIA diagnosis.

ARTHRITIS CARE & RESEARCH (2022)

Article Economics

Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer

Koen Degeling, Maarten J. IJzerman, Catharina G. M. Groothuis-Oudshoorn, Mira D. Franken, Miriam Koopman, Mark S. Clements, Hendrik Koffijberg

Summary: This study aimed to provide guidance on modeling approaches for implementing competing events in discrete event simulations based on censored individual patient data (IPD). Two modeling approaches were compared, and their performance was assessed in terms of event incidence difference and time-to-event distribution. The study found that the level of censoring, number of events, and distribution overlap impacted the performance. Differences in cost-effectiveness estimates were also observed with increasing levels of censoring. Modelers should consider data characteristics when selecting modeling approaches and validate the results appropriately.

VALUE IN HEALTH (2022)

Review Hematology

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman, Maarten J. IJzerman

Summary: This study systematically reviewed the economic evidence for molecular biomarker tests in hematological malignancies and found that while there are promising health economic results, the research in this area is currently limited, with many applications of technological advances yet to be evaluated.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Article Multidisciplinary Sciences

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer

Frederik A. van Delft, Milou Schuurbiers, Mirte Muller, Sjaak A. Burgers, Huub H. van Rossum, Maarten J. IJzerman, Hendrik Koffijberg, Michel M. van den Heuvel

Summary: This study compares nine prediction methods using longitudinal tumor biomarker data to accurately and with a low false positive rate predict non-response to immunotherapy in NSCLC patients. The study evaluated nine models of varying complexity and demonstrated the usefulness of longitudinal biomarker data in predicting treatment response.

HELIYON (2022)

Article Health Policy & Services

Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports

Joost J. Enzing, Saskia Knies, Jop Engel, Maarten J. IJzerman, Beate Sander, Rick Vreman, Bert Boer, Werner B. F. Brouwer

Summary: Despite the high attention given to manufacturers' costs in relation to drug prices in public and academic debates, this issue does not seem to be explicitly and systematically considered in reimbursement reports for expensive drugs.

COST EFFECTIVENESS AND RESOURCE ALLOCATION (2022)

Review Health Policy & Services

Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence

Victoria Freeman, Suzanne Hughes, Chelsea Carle, Denise Campbell, Sam Egger, Harriet Hui, Sarsha Yap, Silvia Deandrea, Michael Caruana, Tonia C. Onyeka, Maarten J. IJzerman, Ophira Ginsburg, Freddie Bray, Richard Sullivan, Ajay Aggarwal, Stuart J. Peacock, Kelvin K. W. Chan, Timothy P. Hanna, Isabelle Soerjomataram, Dianne L. O'Connell, Julia Steinberg, Karen Canfell

Summary: This study conducted a systematic review on the risk of COVID-19-related death for patients with and without cancer. The results showed that individuals with pre-existing cancer diagnosis have a higher risk of COVID-19-related death, although the risk is reduced after adjusting for age.

JOURNAL OF CANCER POLICY (2022)

Review Health Policy & Services

The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence

Chelsea Carle, Suzanne Hughes, Victoria Freeman, Denise Campbell, Sam Egger, Michael Caruana, Harriet Hui, Sarsha Yap, Silvia Deandrea, Tonia C. Onyeka, Maarten J. IJzerman, Ophira Ginsburg, Freddie Bray, Richard Sullivan, Ajay Aggarwal, Stuart J. Peacock, Kelvin K. W. Chan, Timothy P. Hanna, Isabelle Soerjomataram, Dianne L. O'Connell, Karen Canfell, Julia Steinberg

Summary: The early literature on susceptibility to SARS-CoV-2/COVID-19 for people with cancer is characterized by biases and limited data. To provide high-quality evidence for decision-making, studies should control for other potential modifiers of infection risk and perform stratified analyses.

JOURNAL OF CANCER POLICY (2022)

Article Health Care Sciences & Services

The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact

Deon Lingervelder, Michelle M. A. Kip, Eva D. Wiese, Hendrik Koffijberg, Maarten J. Ijzerman, Ron Kusters

Summary: This study investigated the experiences of chronic care patients with blood sampling and their expectations of an at-home blood-sampling device. The results showed that the majority of patients prefer using such a device to monitor their chronic disease. Cost analysis indicated that implementing an at-home blood-sampling device increases the cost of phlebotomy, but reduces overall societal costs mainly due to limiting productivity loss.

BMC HEALTH SERVICES RESEARCH (2022)

Review Multidisciplinary Sciences

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Yoon-Jung Kang, Sophie O'Haire, Fanny Franchini, Maarten IJzerman, John Zalcberg, Finlay Macrae, Karen Canfell, Julia Steinberg

Summary: This study provides an overview and meta-analysis of the prevalence of dMMR/MSI/high TMB in different cancers. The results show variations in the prevalence of these biomarkers across different cancer types. These findings are important for forecasting the budget impact of drug approvals based on these pan-tumour biomarkers in health technology assessments.

SCIENTIFIC REPORTS (2022)

Article Health Care Sciences & Services

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, Robert K. Mahar, Edmond M. Kwan, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun A. Azad, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Christopher Steer, Stephen Brown, Peter Gibbs, Ben Tran, Maarten IJzerman

Summary: The health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) are unclear.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2023)

Review Oncology

A systematic review of methodological considerations in time to diagnosis and treatment in colorectal cancer research

Allison Drosdowsky, Karen E. Lamb, Rebecca J. Bergin, Lucy Boyd, Kristi Milley, Maarten J. IJzerman, Jon D. Emery

Summary: Research on timely diagnosis and treatment of colorectal cancer is important for improving patient outcomes. This systematic review identified methodological issues in previous research, including arbitrary categorization and lack of adjustment for confounders. Recommendations include avoiding artificial categorization, ensuring proper sequencing of key events, and using theoretical frameworks to detect and reduce bias.

CANCER EPIDEMIOLOGY (2023)

Article Rheumatology

What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey

Gillian R. Currie, Catherina G. M. Groothuis-Oudshoorn, Marinka Twilt, Michelle M. A. Kip, Maarten J. IJzerman, Susanne M. Benseler, Joost F. Swart, Sebastiaan J. Vastert, Nico M. Wulffraat, Rae Yeung, Deborah A. Marshall

Summary: The care for JIA patients has changed in the biologics era, however, biologics have important risks and are expensive. Flares after biologic withdrawal are common, but there is little clinical guidance on which patients can safely discontinue their biologics. We conducted a survey to identify the characteristics that are important to pediatric rheumatologists when considering withdrawal of biologics.

CLINICAL RHEUMATOLOGY (2023)

Article Oncology

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care

Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Ake Levin, Charles G. Mullighan, Reinhard Buettner, Trevor J. Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, Torsten Haferlach, Stefan Froehling, Vaidehi Jobanputra

Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.

JCO PRECISION ONCOLOGY (2022)

Article Economics

Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force

William Padula, Noemi Kreif, David J. Vanness, Blythe Adamson, Juan-David Rueda, Federico Felizzi, Pall Jonsson, Maarten J. IJzerman, Atul Butte, William Crown

Summary: Advances in machine learning and artificial intelligence have great potential benefits in healthcare, including health economics and outcomes research. Machine learning can enhance these areas by analyzing big data effectively. However, a lack of transparency in how machine learning methods deliver solutions, especially in unsupervised circumstances, increases risk when using machine learning results.

VALUE IN HEALTH (2022)

Article Health Care Sciences & Services

Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study

Gillian R. Currie, Tram Pham, Marinka Twilt, Maarten J. IJzerman, Pauline M. Hull, Michelle M. A. Kip, Susanne M. Benseler, Glen S. Hazlewood, Rae S. M. Yeung, Nico M. Wulffraat, Joost F. Swart, Sebastian J. Vastert, Deborah A. Marshall

Summary: This study explores pediatric rheumatologists' approaches to treatment decision making for biologics in JIA, identifying attributes influencing initiation and tapering. Five pediatric rheumatologists participated in interviews, outlining varied tapering strategies. Fourteen attributes were selected for a BWS survey, covering patient characteristics and contextual factors. Additional research is needed to align these characteristics with patient and parent preferences.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2022)

No Data Available